Clinical Characteristics and Prognosis of Children with Myelodysplastic Syndrome.
10.19746/j.cnki.issn.1009-2137.2022.01.032
- Author:
Xia ZHENG
1
;
Ji-Xin XU
2
;
Wei-Qin JIANG
3
;
Ling-Jun KONG
4
;
Wen-Li ZHAO
5
Author Information
1. Department of Pediatrics, Huashan Hospital North Fudan University, Shanghai 201900, China.
2. Department of Hematology, Zhengzhou Children's Hospital, Zhengzhou 450000, Henan Province, China.
3. Department of Emergency, Children's Hospital of Shanghai, Shanghai 200333, China.
4. Department of Hematology, Children's Hospital of Soochow University, Suzhou 215025, Jiangsu Province, China.
5. Department of Hematology, SJTU Affiliated Sixth People's Hospital South Campus, Shanghai Fengxian District Central Hospital, Shanghai 201400, China ,E-mail: wenlizhao69@163.com.
- Publication Type:Journal Article
- Keywords:
children;
clinical characteristics;
myelodysplastic syndrome;
prognosis;
risk stratification
- MeSH:
Child;
Female;
Hematopoietic Stem Cell Transplantation;
Humans;
Male;
Myelodysplastic Syndromes/therapy*;
Prognosis;
Retrospective Studies;
Treatment Outcome
- From:
Journal of Experimental Hematology
2022;30(1):195-200
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To analyze the clinical characteristics and prognosis of 40 children with myelodysplastic syndrome (MDS), and provide ideas for clinical diagnosis and treatment.
METHODS:The clinical characteristics, risk stratification, and different treatment regimens of 40 cases with MDS admitted in Department of Hematology of Children's Hospital of Soochow University from January 1, 2011 to December 31, 2017 was retrospectively analyzed. Kaplan-Meier survival curve were used to estimate 3-year overall survival (OS) rate and event-free survival (EFS) rate.
RESULTS:In 40 cases, the ratio of male to female was 1.4∶1.0, male was more than female, and median age was 6.0 years old. Among them, refractory cytopenia (MDS-RCC) was the most common type, and 11 cases were chromosomal abnormalities, 21 cases genetic abnormalities. Fifteen cases accepted hematopoietic stem cell transplantation (HSCT) treatment, while 25 cases did not but drug therapy alone. The 3-year OS rate of the cases who accepted HSCT or not was (72.2±12.2)% and (35.3±10.2)% (P=0.039), 3-year EFS rate was (65.0±12.9)% and (19.2±8.4)% (P=0.012), respectively. Cox regression analysis showed that age < 7 years old (P=0.0333), initial diagnosed platelet < 50×109/L (P=0.007), presence of complex karyotypes and/or gene mutations (P=0.0002), and treatment without HSCT (P=0.016) were the high-risk factors of prognosis. All the children were classified according to IPSS, WPSS and IPSS-R, while analysis result showed that the above three risk assessment had limitations for risk assessment of MDS in children, they could not comprehensively assess the prognosis of children with MDS.
CONCLUSION:MDS-RCC in children is more common. Cox multivariate analysis shows that age < 7 years old, initial diagnosed platelet < 50×109/L, presence of complex karyotypes and/or gene mutation, and treatment without HSCT are the high-risk factors of prognosis in children with MDS. HSCT is the most effective treatment to cure children with MDS at present. The current methods such as IPSS-R commonly used in assessment of prognosis in children with MDS show obvious limitation.
